Publications (depuis 2005)
Differentiation associated regulation of microRNA expression in vivo in human CD8+ T cell subsets. Salaun B, Yamamoto T, Badran B, Tsunetsugu-Yokota Y, Roux A, Baitsch L, Rouas R, Fayyad-Kazan H, Baumgartner P, Devevre E, Ramesh A, Braun M, Speiser D, Autran B, Martiat P, Appay V, Romero P. J Transl Med. 2011 Apr 20;9(1):44.
Cytotoxic responses to BLV tax oncoprotein do not prevent leukemogenesis in sheep. Van den Broeke A, Oumouna M, Beskorwayne T, Szynal M, Cleuter Y, Babiuk S, Bagnis C, Martiat P, Burny A, Griebel P. Leuk Res. 2010 Dec;34(12):1663-9.
Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Najar M, Raicevic G, Boufker HI, Fayyad-Kazan H, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Tissue Eng Part A. 2010 Nov;16(11):3537-46.
Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Najar M, Raicevic G, Id Boufker H, Stamatopoulos B, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Exp Hematol. 2010 Oct;38(10):922-32.
Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase. Fayyad-Kazan H, Rouas R, Merimi M, El Zein N, Lewalle P, Jebbawi F, Mourtada M, Badran H, Ezzeddine M, Salaun B, Romero P, Burny A, Martiat P, Badran B. J Biol Chem. 2010 Jul 2;285(27):20481-91.
The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. Id Boufker H, Lagneaux L, Najar M, Piccart M, Ghanem G, Body JJ, Journé F. BMC Cancer. 2010 Jun 17;10:298.
Dendritic cells generated in clinical grade bags strongly differ in immune functionality when compared with classical DCs generated in plates. Rouas R, Akl H, Fayyad-Kazan H, El Zein N, Badran B, Nowak B, Duvillier H, Martiat P, Lewalle P. J Immunother. 2010 May;33(4):352-63.
Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Raicevic G, Rouas R, Najar M, Stordeur P, Boufker HI, Bron D, Martiat P, Goldman M, Nevessignsky MT, Lagneaux L. Hum Immunol. 2010 Mar;71(3):235-44.
Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Najar M, Raicevic G, Boufker HI, Fayyad Kazan H, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Cell Immunol. 2010;264(2):171-9.
Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, Lagneaux L. Leukemia. 2009 Dec;23(12):2281-9.
Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Najar M, Rouas R, Raicevic G, Boufker HI, Lewalle P, Meuleman N, Bron D, Toungouz M, Martiat P, Lagneaux L. Cytotherapy. 2009;11(5):570-83.
In vitro study of matrix metalloproteinase/tissue inhibitor of metalloproteinase production by mesenchymal stromal cells in response to inflammatory cytokines: the role of their migration in injured tissues. Tondreau T, Meuleman N, Stamatopoulos B, De Bruyn C, Delforge A, Dejeneffe M, Martiat P, Bron D, Lagneaux L. Cytotherapy. 2009;11(5):559-69.
Epigenetics and leukemia: unraveling oncogenic processes in the BLV ovine model. Merimi M, Ozkan Y, Cleuter Y, Griebel P, Burny A, Martiat P, Van den Broeke A. Front Biosci (Schol Ed). 2009 Jun 1;1:154-63. Review.
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Rouas R, Fayyad-Kazan H, El Zein N, Lewalle P, Rothé F, Simion A, Akl H, Mourtada M, El Rifai M, Burny A, Romero P, Martiat P, Badran B. Eur J Immunol. 2009 Jun;39(6):1608-18.
Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. Stamatopoulos B, Haibe-Kains B, Equeter C, Meuleman N, Sorée A, De Bruyn C, Hanosset D, Bron D, Martiat P, Lagneaux L. Haematologica. 2009 Jun;94(6):790-9.
microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, Heimann P, Martiat P, Bron D, Lagneaux L. Blood. 2009 May 21;113(21):5237-45.
Deregulation of calcium fluxes in HTLV-I infected CD4-positive T-cells plays a major role in malignant transformation. Akl H, Badran B, El Zein N, Dobirta G, Burny A, Martiat P. Front Biosci. 2009 Jan 1;14:3925-34. Review.
Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. Meuleman N, Stamatopoulos B, Dejeneffe M, El Housni H, Lagneaux L, Bron D. Leukemia. 2008 Oct;22(10):1882-90.
Gene expression pattern of functional neuronal cells derived from human bone marrow mesenchymal stromal cells. Tondreau T, Dejeneffe M, Meuleman N, Stamatopoulos B, Delforge A, Martiat P, Bron D, Lagneaux L. BMC Genomics. 2008 Apr 11;9:166.
Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P, Bron D, Lagneaux L. Clin Chem. 2007 Oct;53(10):1757-66.
Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D. Exp Hematol. 2007 Oct;35(10):1527-37.
Progressive loss of CD3 expression after HTLV-I infection results from chromatin remodeling affecting all the CD3 genes and persists despite early viral genes silencing. Akl H, Badran B, Dobirta G, Manfouo-Foutsop G, Moschitta M, Merimi M, Burny A, Martiat P, Willard-Gallo KE. Virol J. 2007 Sep 6;4:85.
Complete suppression of viral gene expression is associated with the onset and progression of lymphoid malignancy: observations in Bovine Leukemia Virus-infected sheep. Merimi M, Klener P, Szynal M, Cleuter Y, Bagnis C, Kerkhofs P, Burny A, Martiat P, Van den Broeke A. Retrovirology. 2007 Jul 23;4:51.
Suppression of viral gene expression in bovine leukemia virus-associated B-cell malignancy: interplay of epigenetic modifications leading to chromatin with a repressive histone code. Merimi M, Klener P, Szynal M, Cleuter Y, Kerkhofs P, Burny A, Martiat P, Van den Broeke A. J Virol. 2007 Jun;81(11):5929-39.
HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation. Akl H, Badran BM, Zein NE, Bex F, Sotiriou C, Willard-Gallo KE, Burny A, Martiat P. Leukemia. 2007 Apr;21(4):788-96. Epub 2007 Feb 8. Erratum in: Leukemia. 2009 Nov;23(11):2187. Zein, N E [corrected to Zein, N El].
Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F, Velu T. Cancer Immunol Immunother. 2006 Jul;55(7):819-29.
Human marrow mesenchymal stem cell culture: serum-free medium allows better expansion than classical alpha-MEM medium. Meuleman N, Tondreau T, Delforge A, Dejeneffe M, Massy M, Libertalis M, Bron D, Lagneaux L. Eur J Haematol. 2006 Apr;76(4):309-16.
Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells. Klener P, Szynal M, Cleuter Y, Merimi M, Duvillier H, Lallemand F, Bagnis C, Griebel P, Sotiriou C, Burny A, Martiat P, Van den Broeke A. J Virol. 2006 Feb;80(4):1922-38.
Allogenic hematopoietic stem cell transplantation for malignant disease: how to prevent graft-versus-host disease without jeopardizing the graft-versus-tumor effect? Lewalle P, Rouas R, Martiat P. Drug Discovery Today: Therapeutic Strategies. 2006;3(1):25-30.
Ex vivo expansion of neutrophil precursor cells from mobilized peripheral blood cells: similar results in cancer patients and normal donors. De Bruyn C, Delforge A, Martiat P, Bron D. Cytotherapy. 2005;7(6):470-7.
Defective CD3gamma gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome. Willard-Gallo KE, Badran BM, Ravoet M, Zerghe A, Burny A, Martiat P, Goldman M, Roufosse F, Sibille C. Exp Hematol. 2005 Oct;33(10):1147-59.
Ex vivo expansion of megakaryocyte progenitor cells: cord blood versus mobilized peripheral blood. De Bruyn C, Delforge A, Martiat P, Bron D. Stem Cells Dev. 2005 Aug;14(4):415-24.
6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Ravoet M, Sibille C, Roufosse F, Duvillier H, Sotiriou C, Schandené L, Martiat P, Goldman M, Willard-Gallo KE. Haematologica. 2005 Jun;90(6):753-65.
Transcriptional regulation of the human CD3 gamma gene: the TATA-less CD3 gamma promoter functions via an initiator and contiguous Sp-binding elements. Badran BM, Kunstman K, Stanton J, Moschitta M, Zerghe A, Akl H, Burny A, Wolinsky SM, Willard-Gallo KE. J Immunol. 2005 May 15;174(10):6238-49. |
+32 2 541 31 11